EDAP Edap Tms S.A. ADS

EDAP Announces Proposed Public Offering of American Depositary Shares

EDAP Announces Proposed Public Offering of American Depositary Shares

LYON, France, September 22, 2022 -- EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today that it has commenced a public offering of its American Depositary Shares, or ADSs, each representing one ordinary share of the Company. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.

Jefferies LLC is acting as the sole book-running manager for the offering.

A shelf registration statement on Form F-3 (including a prospectus) relating to the Company’s American Depositary Shares was filed with the Securities and Exchange Commission (the “SEC”) on April 7, 2021 and is effective. The Company has also filed a base prospectus dated April 16, 2021 and a preliminary prospectus supplement dated September 22, 2022 with respect to the proposed offering. Before purchasing ADSs in the offering, you should read the preliminary prospectus supplement and the accompanying prospectus, together with the documents incorporated by reference therein. You may obtain these documents for free by visiting EDGAR on the SEC’s website at . Alternatively, a copy of the preliminary prospectus supplement (and accompanying prospectus) relating to the offering may be obtained from Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at +1 (877) 821-7388 or by email at .

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. In particular, no public offering of the ADSs will be made in Europe.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s proposed follow-on offering. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, but are not limited to, uncertainties related to market conditions, those risks relating to the offering and others described in the preliminary prospectus supplement and in particular in the sections “Forward-Looking Information” and “Risk Factors” and those risks relating to the Company’s business, which are described in the Company’s filings with the Securities and Exchange Commission and in particular in the section “Risk Factors” in the Company's Annual Report on Form 20-F. The Company undertakes no obligation to update or revise any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release, except as required by law.

Company Contact

Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

50

Investor Contact

John Fraunces

LifeSci Advisors, LLC

917-355-2395



EN
22/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Edap Tms S.A. ADS

 PRESS RELEASE

EDAP Announces Positive Final Results from the HIFI Study Comparing Ou...

EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting          Final results demonstrate a significantly higher salvage treatment free survival rate (STFS) at 30 months of 89.6% in the HIFU-treated arm versus 86.2% in patients who underwent radical prostatectomy (RP) Functional evaluation criteria show better results with respect to urinary continence and erectile function in patients receiving HIFU therapy versus patients receivin...

 PRESS RELEASE

EDAP Announces Final Results from HIFI Study Comparing Outcomes of Foc...

EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting LYON, France, April 23, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that final results from the HIFI Study, the largest clinical trial ever conducted comparing EDAP’s Focal One robotic high intensity focused ultrasound (HIFU) versus radical prostatectomy (RP) for the treatment of prostate cancer, will be presented d...

 PRESS RELEASE

EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results

EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results Record Q4 2023 total revenue of EUR 19.6 million ($21.3 million USD) increased 24.8% over Q4 2022Record Q4 2023 HIFU revenue of EUR 7.5 million ($8.1 million USD), an increase of 38.8% over Q4 2022Record full-year 2023 total revenue of EUR 60.4 million ($65.4 million USD) increased 9.6% over full-year 2022Record full-year 2023 HIFU revenue of EUR 20.6 million ($22.3 million USD), an increase of 31.7% over full-year 2022Strong Q4 2023 U.S. Focal One® HIFU procedure growth of +136% year-over-year Company to host conference call ...

 PRESS RELEASE

EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results o...

EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024 Company to host conference call and webcast on Wednesday, March 27th at 8:30am EDT LYON, France, March 13, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2023, before the markets open on Wednesday, March 27th, 2024. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chi...

 PRESS RELEASE

EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Se...

EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference LYON, France, March 6, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a virtual presentation and host 1x1 investor meetings at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference, which is being held virtually from March 12-13, 2024. Presentation details: Date:Wednesday, March 13Time:9:20 – 9:50 AM ET Webcast: The live and archived webcast of the ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch